沙库巴曲缬沙坦、贝那普利对AMI患者PCI术后左心室重构的作用  

Effects of Sacubitril-Valsartan and Benazepril on Left Ventricular Remodeling in AMI Patients Post-PCI

作　　者：张巧玲 王艳芳 ZHANG Qiaoling;WANG Yanfang(Department of Cardiology,Xuchang People's Hospital,Xuchang Henan 461000,China;Department of Gynecology,Xuchang People's Hospital,Xuchang Henan 461000,China)

机构地区：[1]许昌市人民医院心血管内一科,河南许昌461000 [2]许昌市人民医院妇科,河南许昌461000

出　　处：《临床研究》2025年第3期104-107,共4页Clinical Research

摘　　要：目的观察沙库巴曲缬沙坦、贝那普利对急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后左心室重构的作用。方法选择2021年3月至2022年3月许昌市人民医院诊断为AMI并进行PCI手术治疗的97例患者,随机分为对照组(n=48)和观察组(n=49),观察组接受沙库巴曲缬沙坦治疗,对照组接受贝那普利治疗。观察两组左心室重构指标变化、治疗前后6 min步行实验(6MWT)和氨基端前脑钠素(NT-proBNP)水平、两组患者治疗期间不良反应以及术后12个月内心脏不良事件(MACE)的发生率。结果治疗6个月、12个月后观察组左心室舒张末期内径、左心室收缩末期内径低于对照组,左心室射血分数高于对照组,差异有统计学意义(P<0.05);治疗后观察组6MWT高于对照组,NT-proBNP水平低于对照组,差异有统计学意义(P<0.05);两组AMI患者不良反应发生率比较,差异无统计学意义(P>0.05);观察组12个月内MACE发生率(2.04%)低于对照组(12.50%),差异有统计学意义(P<0.05)。结论两种药物均能有效延缓AMI患者心室重构的进程,但沙库巴曲缬沙坦对于心室重构患者治疗效果较好,可以更好的改善患者6MWT和NT-proBNP水平,安全性较好,值得临床应用。Objective To observe the effects of sacubitril-valsartan and benazepril on left ventricular remodeling in patients with acute myocardial infarction(AMI)following percutaneous coronary intervention(PCI).Methods From March 2021 to March 2022,97 patients diagnosed with AMI and treated with PCI at Xuchang People's Hospital were randomly divided into a control group(n=48)and an observation group(n=49).The observation group received sacubitril-valsartan,while the control group received benazepril.The changes in indicators of left ventricular remodeling,6-minute walk test(6MWT),and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels before and after treatment,adverse reactions during treatment,and the incidence of major adverse cardiac events(MACE)within 12 months post-surgery were observed for both groups.Results At 6 and 12 months post-treatment,the observation group showed lower left ventricular end-diastolic diameter and left ventricular end-systolic diameter than the control group,and higher left ventricular ejection fraction,with statistically significant differences(P<0.05).After treatment,the 6MWT was higher and NT-proBNP levels were lower in the observation group compared to the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of AMI patients(P>0.05).The incidence of MACE within 12 months was lower in the observation group(2.04%)compared to the control group(12.50%),with statistically significant differences(P<0.05).Conclusion Both medications can effectively delay the process of ventricular remodeling in AMI patients,but sacubitril-valsartan has a better therapeutic effect on ventricular remodeling.It can improve 6MWT and NT-proBNP levels more effectively and has good safety,making it worthy of clinical application.

关 键 词：左心室重构 急性心肌梗死 经皮冠状动脉介入治疗术 沙库巴曲缬沙坦 贝那普利 

分 类 号：R542.22[医药卫生—心血管疾病]